



## Inflammatory environments disrupt both bone formation and bone resorption

Pei-Wen Chu, Yu-Hsu Chen, Chien-Hui Chen and Shau-Kwaun Chen

J Immunol May 1, 2020, 204 (1 Supplement) 224.46;

Article

Info & Metrics

### Abstract

Inflammation has been associated with bone diseases such as osteoporosis and osteoarthritis. Bone loss were reported in the patients of several inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease. However, how inflammation influence bone metabolism remains elusive. The bone loss in inflammatory environments are widely considered as the results of osteoclast overactivation which leads to excessive bone resorption. We previously discovered that osteoclasts induced from RAW macrophage treated with RANKL exhibited different cell properties and gene expression profile with undifferentiated macrophage. In this research we examined the excessive bone resorption hypothesis in *in vitro* systems. RANKL stimulated differentiation of RAW cells into bone-resorptive osteoclasts, and induction of pre-osteoblasts (MC-3T3 E1) into mature osteoblasts are utilized in this research. Inflammatory environments are mimic by treating cultured osteoclast or osteoblast with conditioned medium collected from bone marrow derived macrophage primed with LPS or interferon- $\gamma$ . The pro-inflammatory cytokines inhibit the proliferation and disrupt the expression of genes that are needed for bone formation, such as osteocalcin and collagen. On the other hand, inflammatory environments did not activate osteoclast, nor promote bone resorption. Instead, pro-inflammatory cytokines inhibit osteoclastogenesis and bone resorption, induce mitochondrial dysfunctions and lead to apoptosis of osteoclast. These results indicated that the bone loss developed in the inflammatory environments might be due to the disruption of both bone formation and bone resorption.

Copyright © 2020 by The American Association of Immunologists, Inc.

### We recommend

$\alpha$ -Lipoic Acid Inhibits Inflammatory Bone Resorption by Suppressing Prostaglandin E2 Synthesis

Hyunil Ha et al., J Immunol, 2006

Elevated Response to Type I IFN Enhances RANKL-Mediated Osteoclastogenesis in Usp18-Knockout Mice

Hwa Young Yim et al., J Immunol, 2016

Utility of recombinant Hedgehog proteins and RANKL to generate bone cell models in vitro

Hortensia Soto et al., J Immunol, 2018

IL-10 modulates formation of osteoclasts in murine hemopoietic cultures.

J M Owens et al., J Immunol, 1996

The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the

Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss

Wei Yu et al., J Clin Invest, 2021

RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis

Bomi Lee et al., JCI Insight., 2017

Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin

Darja Andreev et al., J Clin Invest, 2020

A Synthetic Peptide, CK2.3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway

John Nguyen et al., J Dev Biol

Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue

Find out more

Powered by **TREND MD**[← Previous](#)[^ Back to top](#)**In this issue**[The Journal of Immunology](#)[Vol. 204, Issue 1 Supplement](#)[1 May 2020](#)[Table of Contents](#)[🔔 Article Alerts](#)[✉ Email Article](#)[🔗 Citation Tools](#)[↪ Share](#)[Tweet](#)

讚 0

**▼ Related Articles***No related articles found.*[Google Scholar](#)**▶ Cited By...****▶ More in this TOC Section****▶ Similar Articles**

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

[Continue](#)[Find out more](#)

## Navigate

[Home](#)  
[Current Issue](#)  
[Next in The JI](#)  
[Archive](#)  
[Brief Reviews](#)  
[Pillars of Immunology](#)  
[Translating Immunology](#)

## For Authors

[Submit a Manuscript](#)  
[Instructions for Authors](#)  
[About the Journal](#)  
[Journal Policies](#)  
[Editors](#)

## General Information

[Advertisers](#)  
[Subscribers](#)  
[Rights and Permissions](#)  
[Accessibility Statement](#)  
[FAR 889](#)  
[Privacy Policy](#)  
[Disclaimer](#)

## Journal Services

[Email Alerts](#)  
[RSS Feeds](#)  
[ImmunoCasts](#)  
[Twitter](#)



Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767 Online ISSN 1550-6606

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

[Continue](#)

[Find out more](#)